-
BMS Partners with Terray Therapeutics for AI-Driven Drug Discovery
•
Bristol Myers Squibb (BMS; NYSE: BMY) has entered into an agreement with U.S.-based Terray Therapeutics to discover and develop multiple small-molecule drugs in undisclosed therapeutic areas. Under the terms of the agreement, BMS will receive development and commercialization rights, and in return, will provide Terray with upfront payments and potential…
-
BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal
•
Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ: RNA) focused on the discovery, development, and commercialization of cardiology-oriented antibody oligonucleotide conjugates (AOCs). This innovative class of RNA therapeutics merges the specificity of monoclonal antibodies with the precision of oligonucleotide therapies, building on insights…
